Skip to main content

Scientists discover a highly potent antibody against SARS-CoV-2

Researchers involved in the CARE project have isolated a highly potent monoclonal antibody against SARS-CoV-2, one of the most powerful identified so far

Image by by CI Photos via Shutterstock
Image by by CI Photos via Shutterstock 


The goal of the IMI-funded CARE project is to deliver treatments for the current COVID19 outbreak as well as future coronavirus outbreaks. Apart from screening 600,000 compounds across different libraries, they are also investigating antibodies capable of neutralising the virus. The following article describing the discovery of a promising antibody first appeared on the website of l'École Polytechnique Fédérale de Lausanne (EPFL). See the original article here.

Long-lasting, and effective against all variants to date

Scientists at Lausanne University Hospital (CHUV) and EPFL have discovered a highly potent monoclonal antibody that targets the SARS-CoV-2 spike protein and is effective at neutralising all variants of concern identified to date, including the delta variant. Their findings are published in the prestigious journal Cell Reports (read the scientific paper).

The newly identified antibody was isolated using lymphocytes from COVID-19 patients enrolled in the ImmunoCoV study being carried out by CHUV’s Service of Immunology and Allergy. This antibody is one of the most powerful identified so far against SARS-CoV-2. Structural characterisation of the antibody indicates that it binds to an area that is not subjected to mutations of the spike protein. Through this tight interaction, the antibody blocks the spike protein from binding to cells expressing the ACE2 receptor, which is the receptor the virus uses to enter and infect lung cells.

That means the antibody halts the viral replication process, enabling a patient’s immune system to eliminate SARS-CoV-2 from the body. This protective mechanism was proven through in vivo tests on hamsters; specimens that were administered the antibody were protected against infection even after receiving a highly infectious dose.

In addition to its antiviral properties, the new antibody is designed to have a lasting effect in humans. A typical unaltered antibody provides protection for up to 3–4 weeks. But this new one can protect patients for 4–6 months. That makes it an interesting preventive-treatment option for unvaccinated at-risk individuals or for vaccinated individuals who are unable to produce an immune response. Immunocompromised patients, organ transplant recipients and those suffering from certain kinds of cancer could be protected against SARS-CoV-2 by receiving antibody injections two or three times a year.

CHUV and EPFL now plan to build on these promising results in association with a start-up company which will perform clinical development and production of the antibody-containing drug, through cooperation and intellectual property agreements. Clinical trials of the drug should begin in late 2022.

Treatment or prophylaxy

This research was conducted jointly by CHUV’s Service of Immunology and Allergy, headed by Prof. Giuseppe Pantaleo and Dr. Craig Fenwick, and by EPFL’s Laboratory of Virology and Genetics, headed by Prof. Didier Trono and Dr. Priscilla Turelli.

The research team was able to respond to the pandemic and discover this neutralizing antibody so quickly thanks to the multi-year support of the Swiss Vaccine Research Institute. Prof. Pantaleo’s department at CHUV also received support from the Corona Accelerated R&D in Europe (CARE) program, which is part of the Innovative Medicine Initiative (IMI) – a public-private partnership that seeks to address bottlenecks in the drug discovery and development process in Europe. The discovery of this new antibody marks a major step forward in the fight against COVID-19. It opens the door to improved treatments for severe forms of the disease and to enhanced prophylactic measures, especially for patients with weakened immune systems. However, this antibody is not intended to replace COVID-19 vaccines, which remain the most effective way to prevent infection.

Read more

The IMI CARE project

Read the scientific paper in the journal Cell

Visit the EPFL website 

CARE is preparing for the new normal


Related projects: 

Manage your newsletter subscriptions
Stay informed - subscribe to our newsletter.